Sana Biotechnology, Inc. (SANA)Healthcare | Biotechnology | Seattle, United States | NasdaqGS
3.93 USD
-0.16
(-3.912%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.95 +0.02 (0.509%) ⇧ (Aug. 28, 2026, 7:46 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:11 a.m. EDT
The investment case for Sana Biotechnology is defined by a stark disconnect between its deteriorating fundamentals and aggressive speculative positioning. Fundamentally, the business is in distress: it has lost over 84% of its value over the last four years, carries negative earnings and equity, and recently raised capital through a stock sale, which dilutes existing shareholders. The balance sheet shows negative operating cash flow and a return on equity of -153%, signaling that the core operations are burning cash without generating returns. While analysts maintain a 'strong buy' rating with a mean target of $8.43, this optimism relies entirely on the potential success of its islet transplant data, which remains unproven in humans. The short-term outlook is neutral-to-slightly-bearish due to these structural risks, despite the stock trading above its 50-day moving average. The recent price action shows some resilience, but the underlying trajectory is a multi-year decline. The massive options activity—where traders are betting big on a rally while ignoring the downside—is a classic 'lottery ticket' setup common in biotech stocks awaiting clinical results. This speculative fervor creates volatility but does not constitute a sustainable investment thesis given the lack of revenue, negative cash flows, and the high probability of failure inherent in pre-clinical stage biotechs. Investors should view this as a high-risk speculative play rather than a value opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.083648 |
| AutoETS | 0.084074 |
| AutoARIMA | 0.084086 |
| AutoTheta | 0.084171 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.722 |
| Excess Kurtosis | -0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 52.365 |
| Market Cap | 1,176,487,296 |
| Forward P/E | -7.08 |
| Beta | 2.10 |
| Website | https://www.sana.com |
As of Aug. 22, 2026, 3:11 a.m. EDT: Speculators are overwhelmingly bullish, with open interest heavily skewed toward out-of-the-money calls (92-98% of total volume/interest). There is significant positioning at the $7.5 strike for near-term expirations and deep out-of-the-money strikes ($12.5) for longer-dated contracts, suggesting a bet on a major catalyst or binary event. Conversely, put activity is negligible, indicating a lack of hedging against downside risk despite the company's precarious financial state.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44014084 |
| Address1 | 188 East Blaine Street |
| Address2 | Suite 400 |
| All Time High | 44.6 |
| All Time Low | 1.26 |
| Ask | 5.08 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 2,799,630 |
| Average Daily Volume3 Month | 3,121,679 |
| Average Volume | 3,121,679 |
| Average Volume10Days | 2,799,630 |
| Beta | 2.104 |
| Bid | 3.93 |
| Bid Size | 7 |
| Board Risk | 7 |
| Book Value | 0.442 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.93 |
| Current Ratio | 1.379 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.115 |
| Day Low | 3.89 |
| Debt To Equity | 52.365 |
| Display Name | Sana Biotechnology |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -174,186,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.297 |
| Enterprise Value | 1,096,936,320 |
| Eps Current Year | -0.59111 |
| Eps Forward | -0.55511 |
| Eps Trailing Twelve Months | -0.72 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.5366 |
| Fifty Day Average Change | 0.39339995 |
| Fifty Day Average Change Percent | 0.111236766 |
| Fifty Two Week Change Percent | 44.014084 |
| Fifty Two Week High | 6.55 |
| Fifty Two Week High Change | -2.6200001 |
| Fifty Two Week High Change Percent | -0.4 |
| Fifty Two Week Low | 2.61 |
| Fifty Two Week Low Change | 1.3200002 |
| Fifty Two Week Low Change Percent | 0.5057472 |
| Fifty Two Week Range | 2.61 - 6.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,449,000,000 |
| Float Shares | 190,980,112 |
| Forward Eps | -0.55511 |
| Forward P E | -7.0796785 |
| Free Cashflow | 4,125,625 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 142 |
| Fullday Change | -0.16 |
| Fullday Change Percent | -3.91198 |
| Fullday Price | 3.95 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06052 |
| Held Percent Institutions | 0.77589995 |
| Implied Shares Outstanding | 299,360,637 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-04 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. |
| Long Name | Sana Biotechnology, Inc. |
| Market | us_market |
| Market Cap | 1,176,487,296 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_597313585 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -211,822,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,227,378,611 |
| Number Of Analyst Opinions | 7 |
| Open | 4.05 |
| Operating Cashflow | -132,239,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 206 701 7914 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 0.50890535 |
| Post Market Price | 3.95 |
| Post Market Time | 1,787,960,764 |
| Previous Close | 4.09 |
| Price Eps Current Year | -6.648509 |
| Price Hint | 4 |
| Price To Book | 8.891403 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.297 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.44444 |
| Region | US |
| Regular Market Change | -0.16 |
| Regular Market Change Percent | -3.91198 |
| Regular Market Day High | 4.115 |
| Regular Market Day Low | 3.89 |
| Regular Market Day Range | 3.89 - 4.115 |
| Regular Market Open | 4.05 |
| Regular Market Previous Close | 4.09 |
| Regular Market Price | 3.93 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,142,807 |
| Return On Assets | -0.29163998 |
| Return On Equity | -1.5287199 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 299,360,637 |
| Shares Percent Shares Out | 0.14220001 |
| Shares Short | 42,568,975 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 39,736,380 |
| Short Name | Sana Biotechnology, Inc. |
| Short Percent Of Float | 0.24 |
| Short Ratio | 17.24 |
| Source Interval | 15 |
| State | WA |
| Symbol | SANA |
| Target High Price | 12.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.42857 |
| Target Median Price | 7.0 |
| Total Cash | 160,490,000 |
| Total Cash Per Share | 0.536 |
| Total Debt | 80,939,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.72 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.70205 |
| Two Hundred Day Average Change | 0.2279501 |
| Two Hundred Day Average Change Percent | 0.06157402 |
| Type Disp | Equity |
| Volume | 2,142,807 |
| Website | https://www.sana.com |
| Zip | 98,102 |